Santhera Expands Pipeline With Polyphor Cystic Fibrosis Deal
Executive Summary
Santhera has moved into cystic fibrosis via a global licensing deal with Polyphor, expanding its rare disease pipeline.
You may also be interested in...
Santhera Shores Up Finances With Chiesi Deal for Raxone
In a deal that could be worth CHF105m, the Swiss biotech has outlicensed Raxone to Chiesi for the rare eye disease LHON as it concentrates on the drug's filing for Duchenne muscular dystrophy.
Santhera To Snap Up Second DMD Drug As Idorsia Climbs Aboard
Actelion spin-off Idorsia is becoming the largest shareholder in Santhera after deciding its fellow Switzerland-based group is best placed to advance its optioned DMD candidate vamorolone.
Santhera Confident Of Raxone DMD Success Despite Setbacks
The Swiss company believes it has collected sufficient new data on Raxone for Duchenne muscular dystrophy to convince regulators and hopes to file for that indication on both sides of the Atlantic by the end of the first quarter of 2019.